Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers
Authors:
Open Access
- 19 February 2024
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research
- Vol. 26 (1) , 1-19
Abstract
Background: Neoadjuvant chemotherapy (NAC) is the standard of care for patients with early-stage triple negative breast cancers (TNBC). However, more than half of TNBC patients do not achieve a pathological complete response (pCR) after NAC, and residual cancer burden (RCB) is associated with dismal long-term prognosis. Understanding the mechanisms underlying differential treatment outcomes is therefore critical to limit RCB and improve NAC efficiency. Methods: Human TNBC cell lines and patient-derived organoids were used in combination with real-time metabolic assays to evaluate the effect of NAC (paclitaxel and epirubicin) on tumor cell metabolism, in particular glycolysis. Diagnostic biopsies (pre-NAC) from patients with early TNBC were analyzed by bulk RNA-sequencing to evaluate the predictive value of a glycolysis-related gene signature. Results: Paclitaxel induced a consistent metabolic switch to glycolysis, correlated with a reduced mitochondrial oxidative metabolism, in TNBC cells. In pre-NAC diagnostic biopsies from TNBC patients, glycolysis was found to be upregulated in non-responders. Furthermore, glycolysis inhibition greatly improved response to NAC in TNBC organoid models. Conclusions: Our study pinpoints a metabolic adaptation to glycolysis as a mechanism driving resistance to NAC in TNBC. Our data pave the way for the use of glycolysis-related genes as predictive biomarkers for NAC response, as well as the development of inhibitors to overcome this glycolysis-driven resistance to NAC in human TNBC patients.Keywords
Funding Information
- Fonds De La Recherche Scientifique - FNRS
- Fonds Joseph Maisin
- Fondation contre le Cancer
- Fondation Saint Luc
- Université Catholique de Louvain
This publication has 56 references indexed in Scilit:
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014
- Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic TargetsCancer Discovery, 2014
- FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancerThe Breast, 2013
- Relationships between LDH-A, Lactate, and Metastases in 4T1 Breast TumorsClinical Cancer Research, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast CancerJAMA, 2011
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- Adaptive TherapyCancer Research, 2009
- Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant ChemotherapyJournal of Clinical Oncology, 2007
- The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer SubtypesClinical Cancer Research, 2007